logo
Manitoba's first hyperbaric oxygen therapy hub to open

Manitoba's first hyperbaric oxygen therapy hub to open

Inside the chamber: a bed and pillow, a wrist strap, enough space for a 6 ft. 6 in. cotton gown-clad individual.
Outside the chamber: Martin Hiebert, pointing to gauges and a phone attached to the vessel.
'You are in constant conversation with the patient,' Hiebert said.
Ruth Bonneville / Free Press
Martin Hiebert aims to open the St. James clinic at 1863 Portage Ave. on Sept. 1.
Patients haven't yet laid in one of Prairie Hyperbarics' three chambers. Hiebert aims to open the St. James clinic on Sept. 1, marking Manitoba's first hyperbaric oxygen therapy (HBOT) hub.
He gave the Free Press a tour of 1863 Portage Ave. ahead of time.
Up to 21 clients will be treated daily. Health Canada recognizes HBOT as effective in treating 14 conditions. The range of ailments is vast — embolisms, carbon monoxide poisoning, crush injuries, decompression sickness, skin grafts.
Clients will, most often, arrive with a prescription, Hiebert said.
They'll enter a hyperbaric chamber room with three tubular chambers ready to pump a high concentration of oxygen into the body. Hiebert anticipates great demand: another three chambers could arrive within a year.
'The key here is to make (people) feel comfortable,' Hiebert said.
Hence the TVs. Clients lying in each chamber for 80 minutes can watch movies.
Meanwhile, they'll be consuming near-pure oxygen in four 15-minute stretches. Air composed of 94 per cent oxygen will circulate the enclosed tube.
'Compare it to 33 feet down in the water,' Hiebert described. 'That's the amount of pressure you get.'
Ruth Bonneville / Free Press
Martin Hiebert shows Prairie Hyberbarics' oxygen storage room.
Those periods are broken by five-minute stretches of consuming typical breathing air, which has 21 per cent oxygen, via a supplied mask.
It's a therapy that's grown since the 1950s. The goal is to 'fill the blood with enough oxygen to repair tissues and restore normal body function,' a summary by Johns Hopkins Medicine reads.
Hiebert got exposed roughly eight years ago when he had prostate cancer and accompanying organ damage from its treatment.
His oncologist recommended HBOT. However, there were no options in Manitoba, so Hiebert travelled to a Calgary clinic. It cost Manitoba Health around $35,000, Hiebert said.
HBOT clinics have sprouted in Toronto and Vancouver. Several Canadian hospitals have hyperbaric units.
Hiebert and business partner Dr. Karen Moran de Muller will run Prairie Hyperbarics, a private clinic. The College of Physicians and Surgeons of Manitoba has approved Moran de Muller as the site's medical director.
Still pending is the CPSM accreditation needed before the clinic can operate.
The association's Manitoba Quality Assurance Program has been in communication with the clinic, spokeswoman Wendy Elias-Gagnon wrote in an email. The accreditation process hasn't been started, but CPSM will work with Prairie Hyperbarics 'once the clinic is ready.'
'We're very close,' Hiebert said.
Ruth Bonneville / Free Press
Health Canada recognizes HBOT as effective in treating 14 conditions. Hiebert says a session at Prairie Hyperbarics will cost roughly $600.
Later, he showed a thick binder Prairie Hyperbarics must adhere by to meet medical standards.
Hiebert is envisioning athletes among the clients walking through the doors. A session will cost roughly $600, he said.
He underwent 35 sessions in Calgary. An average case might involve daily sessions for 30 days, he said.
He's in the midst of hiring two technicians to monitor treatments.
The chambers can shut down in 120 seconds if need be. Another room holds a large fire extinguisher; it can fill the chamber room in 10 seconds, Hiebert said.
The College of Physicians and Surgeons of Manitoba isn't aware of another accredited hyperbaric oxygen therapy chamber in the province, Elias-Gagnon confirmed. Shared Health doesn't oversee such chambers.
'We're really excited to have something at that level of innovation happening right in St. James,' said Melanie Maher, executive director of the St. James Village BIZ.
'It's really unique to bring it to the neighbourhood.'
The new clinic comes with a $4.6 million start-up price tag, Hiebert said. Each Perry Baromedical hyperbaric chamber cost roughly $225,000. The clinic hasn't received government funding.
Ruth Bonneville / Free Press
Martin Hiebert, founder of Prairie Hyperbarics, underwent 35 HBOT sessions in Calgary eight years ago at the recommendation of his oncologist.
Monday Mornings
The latest local business news and a lookahead to the coming week.
Hiebert believes Prairie Hyperbarics can save Manitoba Health money.
Hyperbaric therapy would only be considered insured for critical care in a tertiary facility attached to care by a specialist, a provincial spokesperson wrote in a statement.
'While the province is open to further review, non-acute treatment is not currently covered in a private clinical setting,' the spokesperson continued.
Hiebert is a marketing executive, and Moran de Muller is a family doctor practising out of Crestview Medical Clinic. Other family doctors may eventually join Prairie Hyperbarics — a wing of the 4,400 sq. ft. facility holds five offices for practitioners.
gabrielle.piche@winnipegfreepress.com
Gabrielle PichéReporter
Gabrielle Piché reports on business for the Free Press. She interned at the Free Press and worked for its sister outlet, Canstar Community News, before entering the business beat in 2021. Read more about Gabrielle.
Every piece of reporting Gabrielle produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates.
Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber.
Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tory request to curb mobile drug site ‘regressive'
Tory request to curb mobile drug site ‘regressive'

Winnipeg Free Press

time4 hours ago

  • Winnipeg Free Press

Tory request to curb mobile drug site ‘regressive'

The operators of Manitoba's only mobile overdose prevention centre decried the Progressive Conservatives as 'fear-mongering' after the party's leader wrote a letter urging Ottawa to deny its application to continue providing services Thursday. Sunshine House's Mobile Overdose Prevention Site — an RV that included a space for people to use drugs around staff members trained in harm reduction — was totalled in a hit-and-run July 2. It featured a machine that can test drugs for dangerous additives and free harm-reduction supplies. The Salvation Army gave the organization a decommissioned ambulance to use, but Sunshine House is in the process of re-applying for the federal exemption that allows them to operate. Tory Leader Obby Khan and PC housing, addictions and homelessness critic Carrie Hiebert said in a news release Thursday they wrote a letter urging federal Health Minister Marjorie Michel to deny that application. Khan pointed to publicly available data showing there were fewer calls to the Winnipeg Fire Paramedic Service about overdoses and fewer naloxone administrations by paramedics while the van was out of commission in July than there was in June. He suggested that shows 'the van is contributing to the number of overdoses' on city streets. 'We're just looking at putting the brakes on this,' Hiebert told the Free Press Thursday. Data sets published by the city show the WFPS administered naloxone 466 times to 264 patients in July, compared with 619 naloxone administrations and 340 patients in June. Hiebert said she and her colleagues are calling for an extended pause to allow for more data-gathering and analysis over the coming months. The MLA for Morden-Winkler also warned restoring services with a decommissioned ambulance could confuse users and members of the public alike about the staff and resources on board. 'We need to look at how (this program is) affecting treatment and recovery. That should be our No. 1 goal, always — treatment and recovery,' she said. Levi Foy, Sunshine House's executive director, dismissed the comments as 'cheap political points to demonize drug users.' The WFPS gave out a particularly high number of naloxone doses in May — 598 — and the next month. The last time there were more than 600 naloxone doses administered in a month was December 2023. The high numbers could mean there was enough naloxone distribution in the community in July, and people might have been more aware of that and less reliant on emergency services, Foy said. 'It's naive, and it's fear mongering to say that our services are contributing to overdose deaths when it's clear our data doesn't support that,' Foy said. 'Anecdotally, the service providers who we partner with all the time, they also will say that when we're not able to operate our services, that they see a spike in responses.' The RV required an exemption under section 56.1 of the federal Controlled Drugs and Substances Act to operate. Summer typically has higher than usual overdose numbers. The average number of naloxone administrations from January to April 2025 was 260. Not all naloxone and other harm reduction is reported to the WFPS, Foy noted. 'It's a very regressive and hateful kind of approach to take to this because at the end of the day, if you take this service off, and then we see a spike, then what's your solution?' Foy said. While the vehicle is out of service, Sunshine House staff are still providing most services near its Logan Avenue building, including handing out harm-reduction supplies and allowing people to use the drug-checking machine. In its most recent annual report, the van recorded more than 26,000 visits from Oct. 28, 2022 to Oct. 31, 2023. There were 7,086 visits to consume drugs, which resulted in 20 overdose incidents, four trips to the hospital and no deaths. There were 81 deaths related to substance use in Manitoba in the first two months of 2025, the most recent data available show. Preliminary data show there were 570 deaths related to substance use in 2024. — with files from Maggie Macintosh Malak AbasReporter Malak Abas is a city reporter at the Free Press. Born and raised in Winnipeg's North End, she led the campus paper at the University of Manitoba before joining the Free Press in 2020. Read more about Malak. Every piece of reporting Malak produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.

VitalHub Reports Second Quarter 2025 Results
VitalHub Reports Second Quarter 2025 Results

Toronto Star

time5 hours ago

  • Toronto Star

VitalHub Reports Second Quarter 2025 Results

Annual Recurring Revenue (ARR)(1) up 55% YoY to $79.6 million Total Revenue up 47% YoY to $23.9 million Adjusted EBITDA(1) up 50% YoY to $6.3 million TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the 'Company' or 'VitalHub') announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three and six months ended June 30, 2025 with the Canadian securities authorities. These documents may be viewed under the Company's profile at 'Momentum continued in the second quarter with annual organic ARR(1) growth of 14% and 26% adjusted EBITDA(1) margin,' said Dan Matlow, CEO of VitalHub. 'We have worked hard to integrate all 2024 acquisitions that we are building toward our targeted consolidated financial profile. We recently closed the larger acquisitions of Canada-based Novari and UK-based Induction. These add established electronic referral, surgical wait list management, and patient engagement solutions to the VitalHub patient flow suite. Inclusive of all activity to date, we have over $40 million of cash and over $90 million of ARR(1), providing the flexibility and scale to continue expanding internationally.' VitalHub's quarterly investor conference call will take place on Friday, August 8, 2025, at 9:00AM EST. To register for the conference call please visit: ARTICLE CONTINUES BELOW Second Quarter 2025 Highlights ARR(1) as at June 30, 2025 was $79,589,081 as compared to $73,687,666 at March 31, 2025, an increase of $5,901,415 or 8%.Over the previous quarter, ARR(1) movement in Q2 2025 from Q1 2025 was attributable to the following: Organic growth of $1,860,849 or 3%. Acquisition growth of $3,870,000 or 5%. Gain of $170,566 due to fluctuations in foreign exchange rates. ARR(1) as at June 30, 2025 was $79,589,081 as compared to $73,687,666 at March 31, 2025, an increase of $5,901,415 or 8%.Over the previous quarter, ARR(1) movement in Q2 2025 from Q1 2025 was attributable to the following: Organic growth of $1,860,849 or 3%. Acquisition growth of $3,870,000 or 5%. Gain of $170,566 due to fluctuations in foreign exchange rates. Revenue of $23,857,548 as compared to $16,237,605 in the equivalent prior year period, an increase of $7,619,943 or 47%. From the date of closing to June 30, 2025, Induction contributed revenue of $480,383. ARR(1) as at June 30, 2025 was $79,589,081 as compared to $73,687,666 at March 31, 2025, an increase of $5,901,415 or 8%.Over the previous quarter, ARR(1) movement in Q2 2025 from Q1 2025 was attributable to the following: Organic growth of $1,860,849 or 3%. Acquisition growth of $3,870,000 or 5%. Gain of $170,566 due to fluctuations in foreign exchange rates. Revenue of $23,857,548 as compared to $16,237,605 in the equivalent prior year period, an increase of $7,619,943 or 47%. From the date of closing to June 30, 2025, Induction contributed revenue of $480,383. Gross profit as a percentage of revenue was 81% in Q2 2025 and Q2 2024. Net income before income taxes of $2,255,226 as compared to $1,383,605 in the equivalent prior year period, an increase of $871,621 or 63%. EBITDA(1) of $3,599,683 as compared to $1,972,452 in the equivalent prior year period, an increase of $1,627,231 or 82%. Adjusted EBITDA(1) of $6,304,647 or 26% of revenue, as compared to $4,193,985 or 26% of revenue in the equivalent prior year period, an increase of $2,110,662 or 50%. Six Month 2025 Highlights ARR(1) as at June 30, 2025 was $79,589,081 as compared to $51,283,570 at June 30, 2024, an increase of $28,305,511 or 55%.Over the previous year, ARR(1) movement in Q2 2025 from Q2 2024 was attributable to the following: Organic growth of $7,329,129 or 14%. Acquisition growth of $18,470,000 or 36%. Gain of $2,506,382 due to fluctuations in foreign exchange rates. ARR(1) as at June 30, 2025 was $79,589,081 as compared to $51,283,570 at June 30, 2024, an increase of $28,305,511 or 55%.Over the previous year, ARR(1) movement in Q2 2025 from Q2 2024 was attributable to the following: Organic growth of $7,329,129 or 14%. Acquisition growth of $18,470,000 or 36%. Gain of $2,506,382 due to fluctuations in foreign exchange rates. Revenue of $45,532,514 as compared to $31,494,396 in the equivalent prior year period, an increase of $14,038,118 or 45%. Gross profit as a percentage of revenue was 81% in the first six months of 2025 and 2024. Net income before income taxes of $3,742,639 as compared to net income before income taxes of $3,362,500 in the equivalent prior year period, a increase of $380,139 or 11%. EBITDA(1) of $6,750,057 compared to $5,071,468 in the prior year, an increase of $1,678,589 or 33%. Adjusted EBITDA(1) of $11,919,333 or 26% of revenue, compared to $8,238,917 or 26% of revenue in the equivalent prior year period, an increase of $3,680,416 or 45%. Cash on hand as at June 30, 2025 was $94,008,665 compared to $56,574,904 as at December 31, 2024. The Company arranged a $15,000,000 loan to finance an acquisition and fully repaid the balance subsequent to quarter-end. On July 4, 2025, the Company acquired all of the issued and outstanding shares of Novari Health Inc. and its subsidiaries ('Novari') for total consideration of approximately $35.8 million in cash and the issuance of 733,726 common shares of VitalHub. Novari's platform offers a series of integrated software modules providing referral management, surgical wait list management, central intake, and care coordination. With the addition of the ARR(1) of Novari subsequent to the quarter, the Company's pro forma ARR(1) as at June 30, 2025, is approximately $91.6 million. (1) Non-IFRS measure. Disclaimers and reconciliations can be found in SEDAR filings. About VitalHub VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit and LinkedIn. Contact Information Christian Sgro, CPA, CA, CFA Head of IR and M&A Specialist (365) 363-6433 Dan Matlow Chief Executive Officer, Director (416) 727-9061 Cautionary Statement Certain statements contained in this news release may constitute 'forward-looking information' or 'financial outlook' within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'is expected', 'expects', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store